247 related articles for article (PubMed ID: 12777861)
21. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
Birkeland SA; Hamilton-Dutoit S; Bendtzen K
Transplantation; 2003 Jul; 76(1):153-8. PubMed ID: 12865802
[TBL] [Abstract][Full Text] [Related]
22. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
23. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
[TBL] [Abstract][Full Text] [Related]
24. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
Shibasaki S; Yamashita K; Goto R; Wakayama K; Tsunetoshi Y; Zaitsu M; Igarashi R; Haga S; Ozaki M; Umezawa K; Todo S
Transplantation; 2013 Feb; 95(4):542-50. PubMed ID: 23269193
[TBL] [Abstract][Full Text] [Related]
25. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
Valantine H; Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
27. Long-term maintenance therapy for post-cardiac transplant monoclonal lymphoproliferative disorder: caveat mammalian target of rapamycin.
Khalpey Z; Miller DV; Schmitto JD; Kushwaha SS
Transplant Proc; 2011 Jun; 43(5):1893-9. PubMed ID: 21693296
[TBL] [Abstract][Full Text] [Related]
28. Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection.
Aharoni R; Yussim A; Sela M; Arnon R
Int Immunopharmacol; 2005 Jan; 5(1):23-32. PubMed ID: 15589456
[TBL] [Abstract][Full Text] [Related]
29. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma.
Jiménez-Rivera C; Avitzur Y; Fecteau AH; Jones N; Grant D; Ng VL
Pediatr Transplant; 2004 Jun; 8(3):243-8. PubMed ID: 15176961
[TBL] [Abstract][Full Text] [Related]
30. Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD).
Giraldi E; Provenzi M; Fiocchi R; Colledan M; Cornelli P; Torre G; Rambaldi A; Conter V
Pediatr Blood Cancer; 2011 Aug; 57(2):324-8. PubMed ID: 21294246
[TBL] [Abstract][Full Text] [Related]
31. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
32. LF 15-0195, a novel immunosuppressive agent prevents rejection and induces operational tolerance in a mouse cardiac allograft model.
Zhou D; O'Brien C; Shum J; Garcia B; Min W; Jevnikar AM; Dutartre P; Zhong R
Transplantation; 2003 Aug; 76(4):644-50. PubMed ID: 12973102
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
Lehmkuhl H; Hetzer R
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
[TBL] [Abstract][Full Text] [Related]
34. Prolongation of cardiac allograft survival by rapamycin and the invariant natural killer T cell glycolipid agonist OCH.
Haeryfar SM; Lan Z; Leon-Ponte M; Duffy KR; Ge W; Liu W; Mele T; Garcia B; Wang H
Transplantation; 2008 Aug; 86(3):460-8. PubMed ID: 18698251
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic insights into achievement of cardiac allograft long-term survival by treatment with immature dendritic cells and sub-dose sirolimus.
Tao R; Wang L; Chen CH; Wang SH; Demarco RA; Lotze MT; Thai NL; Fung JJ; Lu L; Qian S
J Heart Lung Transplant; 2006 Mar; 25(3):310-9. PubMed ID: 16507425
[TBL] [Abstract][Full Text] [Related]
36. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
37. Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720.
Weckbecker G; Pally C; Beerli C; Burkhart C; Wieczorek G; Metzler B; Morris RE; Wagner J; Bruns C
Transpl Int; 2010 May; 23(5):543-52. PubMed ID: 20003043
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
Pea F; Baccarani U; Tavio M; Cojutti P; Adani GL; Londero A; Baraldo M; Franceschi L; Furlanut M; Viale P
Ann Pharmacother; 2008 Nov; 42(11):1711-6. PubMed ID: 18812562
[TBL] [Abstract][Full Text] [Related]
39. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
40. Everolimus de novo in liver transplantation.
Calmus Y; Durrbach A
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S247-52. PubMed ID: 20004330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
